information on new approvals and medication safety
Neutralizing IL-23 and Its Targets May Improve Ankylosing Spondylitis
Researchers have identified a unique population of entheseal resident cells that can be activated by interleukin 23 (IL-23). This finding may be key to understanding how dysregulation of IL-23 results in precise inflammation of the entheses.
Educational Leader Honored with Top Rheumatology Award
Paul Emery, MA, MD, receives prestigious Nachman Prize.
Drug Updates
Information on new approvals and medication safety.
Minerals, Mud, Martinis, and Methylprednisone
How the practice of rheumatology differs in America and Europe.
Tech Talk: Apps Put More Rheumatology Information at Fingertips
With more and more mobile devices and apps coming onto the market, more and more information is available to rheumatologists on the go.
A Rheumatologic Perspective on Intimacy and Chronic Illness
Sexual dysfunction is frequently one of the first manifestations of physical illness, but is often not inquired about on routine reviews of systems.
Désirée Van Der Heijde, MD, PhD, a Key Driver of Treatment Advances
Dr. van der Heijde learned early in her career that serendipity often plays a role in clinical research and treatment advances.
The Three-Fold Cord of Rheumatology
How the proverbial three-fold cord applies to rheumatology.
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »